Advertisement

Topics

Janus Pharmaceuticals, Inc Company Profile

16:05 EDT 23rd June 2018 | BioPortfolio

Janus was founded in 2004 by Catalyst Pharma Group Inc. (CPG), a clinical development services company in the United States and aRigen, Inc., a private equity backed bio-medical venture company in Japan. aRigen and CPG identified the value in creating topical formulations of novel anti-infective products discovered in Japan and developing and commercializing these products in the United States.

Location

1111 S. Arroyo Parkway, Suite 200
Pasadena
California
91105
United States of America

Contact

Phone: (626) 568-0762
Fax: (626) 568-8667
Email: ssyed@januspharma.com


News Articles [521 Associated News Articles listed on BioPortfolio]

Janus Kinase Inhibitors: Emerging Applications in Dermatology

Learn about the use of Janus kinase inhibitors, which have become promising treatment options for dermatologic conditions such as psoriasis, atopic dermatitis, alopecia areata, vilitigo, and more. S...

Global and Chinese Cancer Janus Kinase Inhibitor Industry, 2017 Market Research Report [Report Updated: 20122017] Prices from USD $3000

The 'Global and Chinese Cancer Janus Kinase Inhibitor Industry, 20122022 Market Research Report' is a professional and indepth study on the current state of the global Cancer Janus Kinase Inhibitor in...

Autoimmune Disorder Treatment Placed On Fast Track By FDA

NewsCTP-543 is a novel oral Janus kinase (JAK) inhibitor for the treatment of moderate-to-severe alopecia areata, an autoimmune disorder in which the immune system attacks hair follicles, resulting in...

Janus Kinase JAK Inhibitor Pipeline Insight, 2018 [Report Updated: 14022018] Prices from USD $1250

Janus Kinase JAK Inhibitor Pipeline Insight, 2018 report by DelveInsight offers comprehensive insights of the pipeline under development therapeutics scenario and growth prospects across Janus Kinase...

FDA Grants Fast Track Designation to Concert’s CTP-543 for the Treatment of Alopecia Areata

LEXINGTON, Mass.–(BUSINESS WIRE)–Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for CTP-5...

Janus Kinase 1 JAK1 Inhibitor Pipeline Insight, 2018 [Report Updated: 14022018] Prices from USD $1500

Janus Kinase 1 JAK1 Inhibitor Pipeline Insight, 2018 report by DelveInsight offers comprehensive insights of the pipeline under development therapeutics scenario and growth prospects across Janus Kin...

Janus Kinase 3 JAK3 Inhibitor Pipeline Insight, 2018 [Report Updated: 14022018] Prices from USD $1250

Janus Kinase 3 JAK3 Inhibitor Pipeline Insight, 2018 report by DelveInsight offers comprehensive insights of the pipeline under development therapeutics scenario and growth prospects across Janus Kin...

FDA approves Pfizer's Xeljanz for ulcerative colitis

The oral therapy is the first and only Janus kinase (JAK) inhibitor approved in the US for this patient population

Drugs and Medications [270 Associated Drugs and Medications listed on BioPortfolio]

Pur-wash [Niagara Pharmaceuticals Inc.]

Pur-Wash

Bacitracin [Qualitest Pharmaceuticals]

Bacitracin Ointment, USP

Pur-wash [Niagara Pharmaceuticals Inc.]

Pur-Wash Purified Water, 98.3% Ophthalmic Solution Eyewash

Antacid [Major Pharmaceuticals]

Major Pharmaceuticals Antacid Tablets Drug Facts

Eyewash station additive concentrate [Niagara Pharmaceuticals Inc.]

EYEWASH STATION ADDITIVE CONCENTRATE

PubMed Articles [220 Associated PubMed Articles listed on BioPortfolio]

Preparation of polymeric Janus microparticles with hierarchically porous structure and enhanced anisotropy.

Anisotropic Janus particles are of great interest for many applications. It is well known that behavior and utility of Janus particles are highly dependent on their chemistry and geometry. Herein, we ...

Simultaneous two drugs release form Janus particles prepared via polymerization-induced phase separation approach.

Seeded emulsion polymerization of 2-dimethylaminoethylamino methacrylate (DMAEMA) was carried out using monodispersed poly(2-hydroxyehtyl methacrylate) (PHEMA) seeds to produce Janus particles. Three ...

Curvature-mediated assembly of Janus nanoparticles on membrane vesicles.

Besides direct particle-particle interactions, nanoparticles adsorbed to biomembranes experience indirect interactions that are mediated by the membrane curvature arising from particle adsorption. In ...

Letter--Incorporating Real-World Evidence and Patient Value Criteria into Value-Based Frameworks for Relapsed/Refractory Multiple Myeloma.

Orlowski has received research funding from Amgen, BioTheryX, Bristol-Myers Squibb, Celgene Corporation, and Takeda Pharmaceuticals; honoraria from Amgen, Bristol-Myers Squibb, Celgene Corporation, Ja...

Electrospun Hydrophilic Janus Nanocomposites for the Rapid Onset of Therapeutic Action of Helicid.

The oral delivery of active ingredients for the fast onset of therapeutic effects is a well-known method in patients. In this study, a new kind of hydrophilic Janus structural nanocomposites was desig...

Clinical Trials [228 Associated Clinical Trials listed on BioPortfolio]

A Single Center Prospective Randomized Controlled Clinical Study of JANUS Stent in Patients With Coronary Artery Disease

Janus stent is the only marketed drug-eluting stent (DES) without polymer coating as yet in China. The goal of this study is to evaluate the efficacy of JANUS (Tacrolimus eluted stent) i...

This is a Study to Determine the Effect and Safety of an Oral Janus Kinase 2 (JAK2)-Inhibitor in Patients With Multiple Myeloma

The purpose of this study is to determine clinical efficacy and safety of INCB018424, a small molecule Janus kinase (JAK) inhibitor, in patients with refractory or relapsed multiple myelom...

Bioequivalence Study of Torrent Pharmaceuticals Ltd's Nebivolol 20 mg Tablet

Subjects to compare the single dose bioavailability of Torrent's Nebivolol Tablets 20 mg and Bystolic®20 mg Tablets of Forest Pharmaceuticals Inc., USA. Dosing periods of studies were sep...

Bioequivalence Study of Torrent Pharmaceuticals's Ltd's Nebivolol 20 mg Tablet

Subjects to compare the single dose bioavailability of Torrent's Nebivolol Tablets 20 mg and Bystolic 20 mg Tablets of Forest Pharmaceuticals Inc., USA. Dosing periods of studies were sepa...

Study Comparing Citalopram Hydrobromide Tablets 40 mg (Torrent Pharmaceuticals Ltd) and RLD Tablets 40 mg (Manufactured By Forest Pharmaceuticals Inc, Missouri) in 24+2 Normal Healthy Male Subjects in Fed Condition

- Objective: - The objective of this study is to compare the rate and extent of absorption of the Test Product, Citalopram Hydrobromide 40 mg (Torrent Pharmaceutical Li...

Companies [1323 Associated Companies listed on BioPortfolio]

Janus Pharmaceuticals, Inc

Janus was founded in 2004 by Catalyst Pharma Group Inc. (CPG), a clinical development services company in the United States and aRigen, Inc., a private equity backed bio-medical venture company in Jap...

Janus

We offer a broad range of investment options, but our expertise is in growth and risk-managed funds. Some of us are driven by a never-ending search for an information advantage. Others by an unwaverin...

Maelor Pharmaceuticals Ltd.

Maelor is a publicly listed (AIM:MLR) specialist critical care pharmaceuticals and devices company. The Company has developed an expertise in bringing both pharmaceuticals and devices to the market as...

Excaliard Pharmaceuticals, Inc.

Excaliard Pharmaceuticals, Inc., is a venture capital-funded biotechnology company founded in 2007 focused on the development and commercialization of novel and innovative drugs for the amelioration o...

Serenity Pharmaceuticals

Founded in 2007 and located in Milford, Pennsylvania, Serenity Pharmaceuticals is focused on developing products that address urinary conditions that impact the health and well-be...

More Information about "Janus Pharmaceuticals, Inc" on BioPortfolio

We have published hundreds of Janus Pharmaceuticals, Inc news stories on BioPortfolio along with dozens of Janus Pharmaceuticals, Inc Clinical Trials and PubMed Articles about Janus Pharmaceuticals, Inc for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Janus Pharmaceuticals, Inc Companies in our database. You can also find out about relevant Janus Pharmaceuticals, Inc Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Corporate Database Quicklinks



Searches Linking to this Company Record